CORXEL
Latest round
- Series D
Last raised
- Jan 2026
Total raised
- $449M
Investors
- 11
About CORXEL
, trading as CORXEL, operates as a drug developer, specializing in providing drugs for the treatment of critical diseases. The CEO, Yanping Mou, graduated from Shanghai Medical College of Fudan University and worked at pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, and Merck Sharp & Dohme. The company’s pipeline consists of small-molecule therapeutics targeting cardiometabolic indications. Its lead product candidate, CX11, is an oral GLP-1 receptor agonist currently in Phase 2 clinical trials in the United States and Phase 3 trials in China. Additional programs include JX10 for acute ischemic stroke and JX09, a selective aldosterone synthase inhibitor for hypertension.
Who invested in CORXEL
11 investors across 3 rounds
See all investors in CORXEL
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CORXEL
Who invested in CORXEL?
CORXEL has 11 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CORXEL raised?
CORXEL has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did CORXEL last raise money?
CORXEL's most recent round on record is a Series D, in Jan 2026.
What does CORXEL do?
, trading as CORXEL, operates as a drug developer, specializing in providing drugs for the treatment of critical diseases.
Where is CORXEL headquartered?
CORXEL is headquartered in Shanghai, China.
Which VCs invest in companies like CORXEL?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at CORXEL's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like CORXEL? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.